Sara Coca Membribes, GU Clinical Research Fellow at Barts Health NHS Trust, shared on X:
“Pleased to share our latest work, published today in ESMO!
As HER-targeted ADCs continue to evolve, understanding HER1–HER4 co-expression may help inform future drug development and patient selection.
We found that HER receptors are rarely expressed in isolation:
- 96% of tumours expressed ≥2 HER receptors.
- 61% co-expressed all four.
These findings support the biological rationale for HER-targeted ADCs beyond HER2 (particularly emerging HER1/HER3 strategies).
Beyond expression patterns, we observed exploratory associations with platinum response.
- HER1 expression was associated with response rates
- HER3 and HER4 expression were associated with response rates.
- No association was found for HER2.
I’m incredibly grateful to Tom Powles, Charlotte Ackerman and the Barts Cancer Institute team for their mentorship, collaboration and support throughout this project.
Looking forward to seeing where HER-targeted therapies take us next.”
Title: HER1–HER4 expression and co-expression in advanced urothelial carcinoma
Authors: S. Coca Membribes, D.M. Berney, L. Beltran, E. Nally, F. Jackson-Spence, B. Szabados, S. Mariathasan, T. Powles, C. Ackerman.
You can also read: ‘Metastatic Renal Cell Carcinoma in 2026: Frontline Combinations, Post-IO Sequencing, and the Emergence of HIF-2α Inhibition‘
